WO1993018746A1 - Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten - Google Patents
Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten Download PDFInfo
- Publication number
- WO1993018746A1 WO1993018746A1 PCT/EP1993/000496 EP9300496W WO9318746A1 WO 1993018746 A1 WO1993018746 A1 WO 1993018746A1 EP 9300496 W EP9300496 W EP 9300496W WO 9318746 A1 WO9318746 A1 WO 9318746A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- eat
- glyceryl
- weight
- compressed gas
- aerosol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Definitions
- Aerosol compressed gas packs have been used for many different purposes for many years. Aerosol compressed gas packs are pressure-resistant containers from which a pressurized mixture of liquefied propellant and active substance is released by actuating a valve. Compressed gas packs are described, for example, in Sucker, Fuchs and Amsterdamr (editors), Pharmaceutical Technology, Thie e, Stuttgart, 1991, pp. 673 - 688, aerosols and pressurized gas packs are also listed, Pharmaceutical Form Honor, Scientific Publishing Company, Stuttgart, 1985, Pp. 8 - 18 and in Voigt, Textbook of Pharmaceutical Technology, VCh, Weinheim, 1987 on pages 427 - 436. This popular dosage form by Thoma, Aerosole, Disverlag, Frankfurt am Main, 1979 is explained in detail.
- Aerosol compressed gas packs have therefore found widespread use in the treatment of respiratory diseases. They are simple, safe and inexpensive. Possible problems in coordinating the patient's breath and triggering an aerosol shock can either be avoided by expansion chambers ("spacers") inserted between the aerosol pack and the patient's mouth or by special designs of the inhalers in which the inhalation of the patient triggers the aerosol shock.
- spacers expansion chambers
- the formulation according to the invention can also be used as a nasal spray and as an oral spray (lingual and buccal application).
- CFCs fluorinated chlorinated hydrocarbons
- Chlorinated carbon detergents are derived from the following
- non-chlorinated fluorohydrocarbons such as 1, 1, 1, 2-tetraf1 uorethane (TG 134a) or 2H-Heptaf1 uorpropane (TG 227).
- TG 134a about 25% ethanol in order to dissolve the sorbitan tri ol eat (Span ® 85) previously used in aerosol suspensions to a sufficient extent (see EP 372 777 A 2).
- the following compounds can also be used: polyhydric alcohols such as glycerol, esters such as ethyl acetate, ketones such as acetone and hydrocarbons such as hexane and heptane, pentane and isopropanol.
- polyhydric alcohols such as glycerol
- esters such as ethyl acetate
- ketones such as acetone
- hydrocarbons such as hexane and heptane
- pentane and isopropanol A disadvantage of such a high concentration is that there may be signs of dissolution for the active substance in the suspension and thus there is a risk of particle growth.
- Wirkstofftei 1 chen grow over a size of 10 ⁇ m when storing such a suspension, on the one hand it can clog the aerosol venti 1 s, on the other hand it can lead to a reduction in effectiveness up to ineffectiveness of the aerosol, since the Wirkstoffparti kel are no longer able to reach deeper sections of the lung due to their size.
- TG 134a or TG 227 are soluble without or using the smallest amounts of other physiologically compatible solvents
- Pol yoxyethyl en-25-gl ycery1-tr i ol eat represents a substance with the above-mentioned necessary properties (trade name "Tagat® TO"; manufacturer:
- Pol yoxyethyl en-25-gl yceryl-tr 1 ol eat has the following
- the HLB value is 11.3; the hydroxyl number is between 18 and 33; the acid number reaches at most 2; the saponification number is between 75 and 90 and the iodine number between 34 and 40.
- Pol yoxyl ethyl en-25-gl yceryl-triol eat is an amber-colored Liquid.
- Tagat ® 0 is chemically a
- Polyoxyethylene 30 glyceryl monooleate has the following structural formula:
- n approx. 30.
- the HLB value is 16.4; the hydroxyl number is between 50 and 65; the acid number reaches at most 2; Versei fungsza 1 is between 30 and 45 and the iodine number between 15 and 19.
- Tagat®02 is chemically a
- Polyoxyethylene-20-glyceryl monooleate has the following structural formula
- the HLB value is 15.0; the hydroxyl number is between 70 and 85; the acid number reaches at most 2; the saponification number is between 40 and 55 and the iodine number between 21 and 27.
- the solvency of a mixture of TG 134a or TG 227 with 1-2% ethanol for the usual active substances is so low that it does not matter for a possible crystal growth of the active substances.
- HLB value from 11.3 to 16.4 is suitable for this purpose.
- Polyoxyethylene-20-glyceryl monool eat based on an amount of active ingredient used is, for example, between 0.3 and 8000, in particular 5 and 4000 and particularly preferably between 15 and 2500% by weight.
- Examples of analgesics, getics are codeine, diamorphine, di hydromorph in, ergo- ta in, fentanyl, morphine;
- Examples of antiallergics are cromo-glicinic acid, nedocromil;
- Examples of antibiotics are cephalosporins, fusafungin, neoycin, penicillin, pentamidine, streptomycin, sulfonamides, tetracycline;
- Examples of anticholinergics are atropine, atrop i nmethon i tetr, ipratropi umbrom1 d, o itropium bromide, trospium chloride;
- Examples of antihi stami ni ka are azelastine, flezelastine, methapyrilene;
- Examples of anti-inflammatory substances are becloethasone, budesonide, dexamethasone, flunisolide
- the exemplified active ingredients can be used as free bases or acids or as pharmaceutically acceptable salts.
- Counterions that can be used are, for example, physiologically acceptable alkaline earth metal or aluminum alloys or amines and, for example, acetate, benzene sulphonate, benzoate, hydrogen carbonate, hydrogen tartrate, bromide, chloride, iodide, carbonate, citrate, fumarate, malate, maleate, gluconate, lactate, pamonate, hydroxynaphthoate and sulphate can be used.
- Esters can also be used, for example acetate, acetonide, propionate, dipropionate, valerate.
- the amount of Tagat (R) T0, Tagat (R) 0 or Tagat (R) 02, based on the total mixture, composed of active ingredients, propellant gas or partial gas mixture, if appropriate auxiliary substances, is, for example, 0.01% by weight - 5 % By weight, in particular 0.2% by weight - 2.5% by weight and particularly preferably 0.75% by weight - 1.5% by weight.
- cosolvents for example aliphatic alcohols having 2 to 6 carbon atoms or their esters or ketones or polygols.
- examples are ethanol, isopropanol, propylene glycol, acetone, ethyl acetate, n-propanol, preferably ethanol and isopropanol.
- the amount of ethanol or isopropanol, based on the total mixture, is between 0% by weight and 10% by weight, in particular 0.1% by weight to 2% by weight and particularly preferably 0.2% by weight to 1% by weight .
- the addition of further surface-active substances, as listed for example in EP 0 372 777, is of course possible.
- the active ingredients can either be suspended at normal atmospheric pressure, the suspension medium having to be cooled to low temperatures (for example - 35 ° C. to - 55 ° C.) or inside a pressure vessel, with normal temperatures (room temperature 15 ° to 25 ° C) can be worked.
- the suspension is homogenized and then filled into pressure cans, which are closed with a dosing valve or are then closed.
- the suspension With further stirring and cooling, the suspension is filled with cooled blowing agent 227 to 1170.0 g and then filled into metal cans which are closed with metering valves which release 50 ⁇ l of the suspension per stroke. This releases 1 mg cromoglycic acid, disodium salt and 0.5 mg reproterol hydrochloride per stroke.
- the suspension is made up to 1170.0 g with cooled blowing agent 227 and then filled into metal cans which are sealed with Dos 1 ervent 11 s, which release 50 ⁇ l of the suspension per stroke. This releases 1 mg cromoglycic acid, D 1 sodium salt and 0.5 mg reproterol hydrochloride per stroke.
- the suspension With further stirring and cooling, the suspension is filled with cooled blowing agent 227 to 1170.0 g and then filled into metal cans which are closed with metering valves which release 50 ⁇ l of the suspension per stroke. This releases 1 mg cromoglycic acid, diatrium salt and 0.5 mg reproterol hydrochloride per stroke.
- Example 4
- Example 2 The procedure is as in Example 1, but instead of 16.8 g of micronized cromogloleic acid, disodium salt and 8.4 g of micronized reproterol ydrochloride, 16.8 g of micronized D-18024 is used.
- D-18024 has the following structural formula:
- D-18024 carries the INN Fl ezel ast1 nhydrochl ori d
- Example 2 The procedure is as in Example 1, but instead of 16.8 g of micronized Cro ogl 1 c 1 nic acid, disodium salt, 8.4 g of micronized reproterol hydrochloride, 0.9 g of micronized saccharin sodium and 6.75 g of peppermint oil is 4.2 g micronized budesonide is used. One stroke contains 0.25 mg budesonide.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Wrappers (AREA)
- Lubricants (AREA)
- Fats And Perfumes (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Colloid Chemistry (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Filling Or Discharging Of Gas Storage Vessels (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU37459/93A AU664080B2 (en) | 1992-03-17 | 1993-03-04 | Pressurized gas packagings using polyoxyethylene glyceryl-obates |
GEAP19932335A GEP19991518B (en) | 1992-03-17 | 1993-03-04 | Aerosol for Pressurized Gas Cylinders |
DE59306978T DE59306978D1 (de) | 1992-03-17 | 1993-03-04 | Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten |
JP51620193A JP3380242B2 (ja) | 1992-03-17 | 1993-03-04 | ポリオキシエチレン−グリセリルオレアートを使用した圧縮ガスパッキング |
EP93906483A EP0630229B1 (de) | 1992-03-17 | 1993-03-04 | Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten |
KR1019940703219A KR100255261B1 (ko) | 1992-03-17 | 1993-03-04 | 폴리옥시에틸렌 글리세릴 올레에이트를 사용하는 압축 가스 팩키징 |
RU94041703A RU2106862C1 (ru) | 1992-03-17 | 1993-03-04 | Состав аэрозольной упаковки под давлением и способ его получения |
BR9306089A BR9306089A (pt) | 1992-03-17 | 1993-03-04 | Embalagens de gás comprimido utilizando oleatos de polioxietileno-glicerila |
CA002129855A CA2129855C (en) | 1992-03-17 | 1993-03-04 | Pressurized gas packagings using polyoxyethylene glyceryl-oleates |
NO943305A NO307282B1 (no) | 1992-03-17 | 1994-09-07 | Trykkgassforpakninger under anvendelse av polyoksyetylenglyceryl-oleater, samt fremgangsmåte for fremstilling av slike trykkgassforpakninger |
FI944257A FI109875B (fi) | 1992-03-17 | 1994-09-14 | Painekaasupakkauksia, jotka on saatu käyttämällä polyoksietyleeniglyseryylioleaatteja |
GR970402244T GR3024600T3 (en) | 1992-03-17 | 1997-09-02 | Pressurized gas packagings using polyoxyethylene glyceryl-obates. |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4208505.5 | 1992-03-17 | ||
DE4208505 | 1992-03-17 | ||
DEP4215188.0 | 1992-05-08 | ||
DE4215188 | 1992-05-08 | ||
DE4230876A DE4230876A1 (de) | 1992-03-17 | 1992-09-16 | Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten |
DEP4230876.3 | 1992-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993018746A1 true WO1993018746A1 (de) | 1993-09-30 |
Family
ID=27203527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1993/000496 WO1993018746A1 (de) | 1992-03-17 | 1993-03-04 | Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten |
Country Status (25)
Country | Link |
---|---|
US (1) | US5415853A (de) |
EP (1) | EP0630229B1 (de) |
JP (1) | JP3380242B2 (de) |
KR (1) | KR100255261B1 (de) |
CN (3) | CN1069191C (de) |
AT (1) | ATE155680T1 (de) |
AU (1) | AU664080B2 (de) |
BR (1) | BR9306089A (de) |
CA (1) | CA2129855C (de) |
CZ (1) | CZ285135B6 (de) |
DE (2) | DE4230876A1 (de) |
DK (1) | DK0630229T3 (de) |
ES (1) | ES2105233T3 (de) |
FI (1) | FI109875B (de) |
GE (1) | GEP19991518B (de) |
GR (1) | GR3024600T3 (de) |
HK (2) | HK1029046A1 (de) |
HU (1) | HU214914B (de) |
IL (1) | IL105062A (de) |
MX (1) | MX9301450A (de) |
NO (1) | NO307282B1 (de) |
RU (1) | RU2106862C1 (de) |
SK (1) | SK279953B6 (de) |
TW (1) | TW238334B (de) |
WO (1) | WO1993018746A1 (de) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0633019A1 (de) * | 1993-07-08 | 1995-01-11 | ASTA Medica Aktiengesellschaft | Druckgaspackungen unter Verwendung von Polyoxyethylen-glyceryl-fettsäure-estern als Suspensionsstabilisatoren und Ventilschmiermittel |
EP0656212A1 (de) * | 1993-11-30 | 1995-06-07 | Dr. Rentschler Arzneimittel GmbH & Co. | Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung |
WO1995024892A1 (en) * | 1994-03-14 | 1995-09-21 | Abbott Laboratories | Aerosol drug formulations containing vitamin e |
WO1996006598A1 (en) * | 1994-08-26 | 1996-03-07 | Abbott Laboratories | Aerosol drug formulations containing polyglycolyzed glycerides |
WO1996018384A1 (en) * | 1994-12-10 | 1996-06-20 | Glaxo Group Limited | Propellant mixture for aerosol formulation |
US6039932A (en) * | 1996-09-27 | 2000-03-21 | 3M Innovative Properties Company | Medicinal inhalation aerosol formulations containing budesonide |
EP1275374A1 (de) * | 1996-04-12 | 2003-01-15 | Novadel Pharma Inc. | Unpolarer Spray zur bukkalen Anwendung die Alkaloidderivate oder Analgetika enthält |
US6558651B1 (en) | 1995-12-22 | 2003-05-06 | Smithkline Beecham Corporation | Aerosols containing annealed particulate salbutamol and tetrafluoroethane |
US6964759B2 (en) | 2000-02-22 | 2005-11-15 | Chiesi Farmaceutici S.P.A. | Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease |
US6967017B1 (en) | 1999-07-23 | 2005-11-22 | Chiesi Farmaceutici S.P.A. | Formulations of steroid solutions for inhalatory administration |
US7018618B2 (en) | 2000-05-22 | 2006-03-28 | Chiesi Farmaceutici S.P.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
EP1674079A2 (de) | 1998-11-25 | 2006-06-28 | CHIESI FARMACEUTICI S.p.A. | Druckdosierinhalatoren |
US7381402B2 (en) | 2004-02-27 | 2008-06-03 | Chiesi Farmaceutici S.P.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
US7601336B2 (en) | 1997-06-13 | 2009-10-13 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
US7696178B2 (en) | 2001-07-02 | 2010-04-13 | Chiesi Farmaceutici S.P.A. | Optimised formulation of tobramycin for aerosolization |
EP0932397B2 (de) † | 1996-09-27 | 2014-04-02 | Minnesota Mining And Manufacturing Company | Medizinische aerosolformulierungen enthaltend budesonide |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840213A (en) * | 1995-04-28 | 1998-11-24 | Great Lakes Chemical Corporation | Uses of heptafluoropropane |
DE19753108A1 (de) * | 1997-11-29 | 1999-08-05 | Wella Ag | Mittel zur Erhöhung der Formbarkeit und des Glanzes von Haaren |
US6315985B1 (en) * | 1999-06-18 | 2001-11-13 | 3M Innovative Properties Company | C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability |
IT1317720B1 (it) * | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
IT1318514B1 (it) * | 2000-05-12 | 2003-08-27 | Chiesi Farma Spa | Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari. |
KR100947409B1 (ko) * | 2002-03-01 | 2010-03-12 | 키에시 파르마슈티시 엣스. 피. 에이. | 포모테롤 초미세 조성물 |
GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
US20070286814A1 (en) * | 2006-06-12 | 2007-12-13 | Medispray Laboratories Pvt. Ltd. | Stable aerosol pharmaceutical formulations |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0203211A1 (de) * | 1985-05-28 | 1986-12-03 | Chemisch Adviesbureau Drs. J.C.P. Schreuder B.V. | Zusammensetzung zur Behandlung von Hautkrankheiten und Verfahren zu ihrer Herstellung |
WO1987005210A1 (en) * | 1986-03-10 | 1987-09-11 | Kurt Burghart | Pharmaceutical preparation and process for preparing the same |
WO1987005211A1 (en) * | 1986-03-10 | 1987-09-11 | Kurt Burghart | Pharmaceutical preparation and process for producing the same |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4010252A (en) * | 1974-12-19 | 1977-03-01 | Colgate-Palmolive Company | Antimicrobial compositions |
NL7506407A (nl) * | 1975-05-30 | 1976-12-02 | Akzo Nv | Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat. |
US4581225A (en) * | 1984-04-25 | 1986-04-08 | Eli Lilly And Company | Sustained release intranasal formulation and method of use thereof |
US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
GB8828477D0 (en) * | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
IL95952A0 (en) * | 1989-10-19 | 1991-07-18 | Sterling Drug Inc | Aerosol composition for topical medicament |
US4963720A (en) * | 1989-12-05 | 1990-10-16 | Jong Jiunn Neng | Apparatus for counting lump foodstuffs |
-
1992
- 1992-09-16 DE DE4230876A patent/DE4230876A1/de not_active Withdrawn
- 1992-12-23 SK SK3858-92A patent/SK279953B6/sk not_active IP Right Cessation
- 1992-12-23 CZ CS923858A patent/CZ285135B6/cs not_active IP Right Cessation
-
1993
- 1993-03-04 AU AU37459/93A patent/AU664080B2/en not_active Ceased
- 1993-03-04 ES ES93906483T patent/ES2105233T3/es not_active Expired - Lifetime
- 1993-03-04 CA CA002129855A patent/CA2129855C/en not_active Expired - Fee Related
- 1993-03-04 DK DK93906483.8T patent/DK0630229T3/da active
- 1993-03-04 HU HU9402671A patent/HU214914B/hu not_active IP Right Cessation
- 1993-03-04 WO PCT/EP1993/000496 patent/WO1993018746A1/de active IP Right Grant
- 1993-03-04 EP EP93906483A patent/EP0630229B1/de not_active Expired - Lifetime
- 1993-03-04 RU RU94041703A patent/RU2106862C1/ru not_active IP Right Cessation
- 1993-03-04 KR KR1019940703219A patent/KR100255261B1/ko not_active IP Right Cessation
- 1993-03-04 DE DE59306978T patent/DE59306978D1/de not_active Expired - Lifetime
- 1993-03-04 JP JP51620193A patent/JP3380242B2/ja not_active Expired - Fee Related
- 1993-03-04 GE GEAP19932335A patent/GEP19991518B/en unknown
- 1993-03-04 BR BR9306089A patent/BR9306089A/pt not_active Application Discontinuation
- 1993-03-04 AT AT93906483T patent/ATE155680T1/de not_active IP Right Cessation
- 1993-03-16 CN CN93104061A patent/CN1069191C/zh not_active Expired - Fee Related
- 1993-03-16 MX MX9301450A patent/MX9301450A/es unknown
- 1993-03-16 IL IL105062A patent/IL105062A/xx not_active IP Right Cessation
- 1993-03-17 US US08/033,789 patent/US5415853A/en not_active Expired - Lifetime
- 1993-03-18 TW TW082102062A patent/TW238334B/zh not_active IP Right Cessation
-
1994
- 1994-09-07 NO NO943305A patent/NO307282B1/no not_active IP Right Cessation
- 1994-09-14 FI FI944257A patent/FI109875B/fi not_active IP Right Cessation
-
1997
- 1997-09-02 GR GR970402244T patent/GR3024600T3/el unknown
-
1999
- 1999-11-19 CN CN99124841A patent/CN1085525C/zh not_active Expired - Fee Related
- 1999-11-19 CN CN99124842A patent/CN1085526C/zh not_active Expired - Fee Related
-
2000
- 2000-11-10 HK HK00107168A patent/HK1029046A1/xx not_active IP Right Cessation
- 2000-11-17 HK HK00107334A patent/HK1027969A1/xx not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0203211A1 (de) * | 1985-05-28 | 1986-12-03 | Chemisch Adviesbureau Drs. J.C.P. Schreuder B.V. | Zusammensetzung zur Behandlung von Hautkrankheiten und Verfahren zu ihrer Herstellung |
WO1987005210A1 (en) * | 1986-03-10 | 1987-09-11 | Kurt Burghart | Pharmaceutical preparation and process for preparing the same |
WO1987005211A1 (en) * | 1986-03-10 | 1987-09-11 | Kurt Burghart | Pharmaceutical preparation and process for producing the same |
Non-Patent Citations (1)
Title |
---|
JOURNAL DE PHARMACIE DE BELGIQUE Bd. 28, Nr. 2, 1973, BRUXELLES (BE) Seiten 209 - 216 I. DONTCHEVA, ET AL. 'etude comparee de l'effet stabilisant des substances tensio-actives sur des systemes disperses heterogenes' * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0633019A1 (de) * | 1993-07-08 | 1995-01-11 | ASTA Medica Aktiengesellschaft | Druckgaspackungen unter Verwendung von Polyoxyethylen-glyceryl-fettsäure-estern als Suspensionsstabilisatoren und Ventilschmiermittel |
EP0656212A1 (de) * | 1993-11-30 | 1995-06-07 | Dr. Rentschler Arzneimittel GmbH & Co. | Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung |
WO1995024892A1 (en) * | 1994-03-14 | 1995-09-21 | Abbott Laboratories | Aerosol drug formulations containing vitamin e |
WO1996006598A1 (en) * | 1994-08-26 | 1996-03-07 | Abbott Laboratories | Aerosol drug formulations containing polyglycolyzed glycerides |
US5635159A (en) * | 1994-08-26 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing polyglycolyzed glycerides |
WO1996018384A1 (en) * | 1994-12-10 | 1996-06-20 | Glaxo Group Limited | Propellant mixture for aerosol formulation |
US6153173A (en) * | 1994-12-10 | 2000-11-28 | Glaxo Group Limited | Propellant mixture for aerosol formulation |
US6309624B1 (en) | 1994-12-10 | 2001-10-30 | Glaxco Group Limited | Particulate medicament in an aerosol formulation with a propellant and co-propellant |
WO2004073681A1 (en) * | 1995-12-22 | 2004-09-02 | Michael Thomas Riebe | Medicaments |
US6558651B1 (en) | 1995-12-22 | 2003-05-06 | Smithkline Beecham Corporation | Aerosols containing annealed particulate salbutamol and tetrafluoroethane |
US6656453B2 (en) | 1995-12-22 | 2003-12-02 | Smithkline Beecham Corporation | Medicaments |
EP1275374A1 (de) * | 1996-04-12 | 2003-01-15 | Novadel Pharma Inc. | Unpolarer Spray zur bukkalen Anwendung die Alkaloidderivate oder Analgetika enthält |
US6039932A (en) * | 1996-09-27 | 2000-03-21 | 3M Innovative Properties Company | Medicinal inhalation aerosol formulations containing budesonide |
EP0932397B2 (de) † | 1996-09-27 | 2014-04-02 | Minnesota Mining And Manufacturing Company | Medizinische aerosolformulierungen enthaltend budesonide |
US7601336B2 (en) | 1997-06-13 | 2009-10-13 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
US8420058B2 (en) | 1997-06-13 | 2013-04-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
US8142763B2 (en) | 1998-11-25 | 2012-03-27 | Chiesi Farmaceutici S.P.A. | Pressurized metered dose inhalers (MDI) containing a solution comprising ipratropium bromide, HFA propellant, and co-solvent and comprising a container with a specific internal surface composition and/or lining |
EP1674079A2 (de) | 1998-11-25 | 2006-06-28 | CHIESI FARMACEUTICI S.p.A. | Druckdosierinhalatoren |
US7223381B2 (en) | 1998-11-25 | 2007-05-29 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers (MDI) |
US7347199B1 (en) | 1998-11-25 | 2008-03-25 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers (MDI) |
US6967017B1 (en) | 1999-07-23 | 2005-11-22 | Chiesi Farmaceutici S.P.A. | Formulations of steroid solutions for inhalatory administration |
US6964759B2 (en) | 2000-02-22 | 2005-11-15 | Chiesi Farmaceutici S.P.A. | Formulations containing an anticholinergic drug for the treatment of chronic obstructive pulmonary disease |
US7018618B2 (en) | 2000-05-22 | 2006-03-28 | Chiesi Farmaceutici S.P.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
US7939502B2 (en) | 2001-07-02 | 2011-05-10 | Chiesi Farmaceutici S.P.A. | Optimised formulation of tobramycin for aerosolization |
US8168598B2 (en) | 2001-07-02 | 2012-05-01 | Chiesi Farmaceutici S.P.A. | Optimised formulation of tobramycin for aerosolization |
US7696178B2 (en) | 2001-07-02 | 2010-04-13 | Chiesi Farmaceutici S.P.A. | Optimised formulation of tobramycin for aerosolization |
US7381402B2 (en) | 2004-02-27 | 2008-06-03 | Chiesi Farmaceutici S.P.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993018746A1 (de) | Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten | |
EP0633019B1 (de) | Druckgaspackungen unter Verwendung von Polyoxyethylen-glyceryl-fettsäure-estern als Suspensionsstabilisatoren und Ventilschmiermittel | |
EP1809243B1 (de) | Aerosolsuspensionsformulierungen mit tg 227 ea als treibmittel | |
EP1100465B1 (de) | Medizinische aerosolformulierungen | |
DE69313825T2 (de) | Pharmazeutische Aerosole enthaltend Beclometason-dipropionat | |
DE69205177T2 (de) | Pharmazeutische Aerosolformulierung. | |
DE69904312T2 (de) | Pharmazeutische aerosolformulierung | |
DE69224656T2 (de) | Arzneimittel | |
DE69530325T2 (de) | Aerosol-arzneiformulierungen | |
EP1014943B1 (de) | Medizinische aerosolformulierungen | |
DE68924540T3 (de) | Medizinische Aerosolformulierungen. | |
EP1102579B1 (de) | Medizinische aerosolformulierungen | |
DE60019167T2 (de) | Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason | |
DE69828817T2 (de) | Pharmazeutische aerosolzusammensetzungen | |
EP0504112A2 (de) | Pharmazeutische Aerosolformulierungen | |
EP1372608A1 (de) | Medizinische aerosolformulierungen | |
WO1997040824A2 (de) | Treibmittelmischungen und aerosole für die mikronisierung von arzneimitteln mit hilfe dichter gase | |
EP1121112A2 (de) | Lagerfähiges wirkstoffkonzentrat mit formoterol | |
WO2006097556A2 (es) | Nueva formulación estable de aerosoles en suspensión y procedimiento de obtención | |
DE68919642T2 (de) | Arzneimittel. | |
DE102012102218A1 (de) | Ozon nicht abbauende medizinische Aerosolformulierungen | |
PT927037E (pt) | Formulacoes em aerossol de furoato de mometasona sem clorofluorocarbonetos | |
EP1492513B1 (de) | Hfa-suspensionsformulierungen enthaltend ein anticholinergikum | |
DE102004032322A1 (de) | Aerosolsuspensionsformulierungen mit TG 227 ea als Teibmittel | |
DE2831419A1 (de) | Dispersion oder suspension aus lecithin oder einem sorbitan- oder sorbit-ester in treibmittel 12 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MG MN MW NO NZ PL RO RU SD UA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) | ||
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993906483 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2129855 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 944257 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019940703219 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1993906483 Country of ref document: EP |
|
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication | ||
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) | ||
WWG | Wipo information: grant in national office |
Ref document number: 1993906483 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 944257 Country of ref document: FI |